相关实验视频
Updated: Jan 6, 2026
01:19
Mitral Valve Prolapse III: Nursing Management
Published on: June 19, 2025
252
在现场瘤细胞工程逆转免疫逃逸,以增强免疫疗法效果
Shujun Liu1, Shijun Yuan1, Meichen Liu1
1Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Acta pharmaceutica Sinica. B
|March 5, 2025
概括
这项研究在现场设计瘤细胞,通过恢复MHC-I/TSA表达和沉默CD55来克服免疫疗法抵抗,从而扭转瘤免疫抑制微环境 (TIME) 并增强抗瘤免疫力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 瘤免疫逃生通过抗原缺乏和免疫抑制微环境 (TIME) 限制了免疫治疗的有效性.
- 由于瘤细胞积极逃避免疫检测和反应,现有的免疫疗法面临挑战.
研究的目的:
- 开发一种in situ瘤细胞工程策略,以破坏瘤免疫逃逸的源头.
- 恢复瘤细胞MHC-I/瘤特异抗原复合体 (MHC-I/TSA) 表达和沉默CD55以促进T细胞识别和逆转TIME.
主要方法:
- 准备了一种多克索鲁比 (DOX) 和双基因等离子体 (MAC pDNA) 的共载药物递送系统 (LCPN@ACD),具有瘤向和双转换特性.
- 使用LCPN@ACD进行实地瘤细胞工程,以恢复MHC-I/TSA并降低CD55表达.
- 评估了LCPN@ACD诱导的免疫细胞死亡 (ICD),DC成熟,T细胞激活和透.
主要成果:
- LCPN@ACD诱导ICD,促进DC成熟并增强T细胞激活和透.
- 工程瘤细胞表现出恢复的MHC-I/TSA表达,改善了识别和杀死.
- 降低CD55的调节增加了ICOSL+ B细胞和CTLs,有效地逆转了TIME,并提高了αPD-1和CAR-T治疗的疗效.
结论:
- 在现场的瘤细胞工程策略有效地消除了瘤免疫逃逸的来源.
- 这种方法为克服临床癌症免疫疗法的挑战提供了新的策略.
- 恢复MHC-I/TSA和沉默CD55是提高免疫治疗反应的关键.
相关概念视频
01:19Mitral Valve Prolapse III: Nursing Management
252
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
252
01:30Cancer Vaccines
917
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
917
01:22Development of Immunocompetence
759
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
759
01:51Vaccinations
51.1K
Overview
51.1K
01:22Healthcare Associated Infections II: Preventive Measures
3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
01:07Teratogenicity
3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K